BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//jEvents 2.0 for Joomla//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:STANDARD
DTSTART:20251027T073000
RDATE:20260329T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:Europe/Berlin CET
END:STANDARD
BEGIN:STANDARD
DTSTART:20261025T020000
RDATE:20270328T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:Europe/Berlin CET
END:STANDARD
BEGIN:STANDARD
DTSTART:20271031T020000
RDATE:20280326T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:Europe/Berlin CET
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20260329T030000
RDATE:20261025T020000
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:Europe/Berlin CEST
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20270328T030000
RDATE:20271031T020000
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:Europe/Berlin CEST
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:7a40a1c3e2e011e03cfdbf71f76825df
CATEGORIES:Kongresse
CREATED:20260806T175702
SUMMARY:2nd Obesity and Weight Loss Drug Development Summit Europe
LOCATION:HYPERION Hotel Munchen
DESCRIPTION;ENCODING=QUOTED-PRINTABLE:\n\nUncovering Innovative Targets, Emerging Combinations and Patient Phenot
 yping Approaches to Drive Tolerable, Differentiated and Long-Term Efficacio
 us Therapies Through the Clinic\n\n\nURLs:\nBrochure: https://go.evvnt.com/
 3760195-0?pid=1357 \nTickets: https://go.evvnt.com/3760195-2?pid=1357 \nWeb
 site: https://go.evvnt.com/3760195-3?pid=1357\n\n\nDate and Time: On Wed, 2
 8 Oct 2026 07:30 - Thu, 29 Oct 2026 16:15\n\n\nVenue Details: HYPERION Hote
 l Munchen, Truderinger Str. 13, 81677, Munchen, Germany\n\n\nCategory: Conf
 erences | Science, Health and Medicine | Pharmaceuticals\n\n\nPrices:\nDrug
  Developer Pricing - Full Access Pass: EUR 2899.00,\nAcademic Pricing - Ful
 l Access Pass: EUR 2499.00,\nService Provider Pricing - Full Access Pass: E
 UR 3499.00\n\n\nSpeakers: Jacob Jepsen, Chief Scientific Officer, Alveus Th
 erapeutics, Philip Larsen, Chief Executive Officer, Antag Therapeutics, Ste
 ffen-Sebastian Bolz, Chief Scientific Officer, Alphaia Pharma, Paul Little,
  Chief Executive Officer, Atrogi, Matthijs van Haren, Founder and Chief Sci
 entific Officer, Cantoni Therapeutics, Robert Mamoun, Co-Founder and Chief 
 Executive Officer, Ciloa, Martin Brenner, Chief Executive and Chief Scienti
 fic Officer, iBio, Brent Meadows, Chief Business Officer, Senovia Bioscienc
 es, Xavier Jacq, Chief Scientific Officer, MitoRx Therapeutics, Daniel Mark
 graf, Head of Laboratory, Boehringer Ingelheim, Volker Mack, Senior Princip
 al Scientist, Boehringer Ingelheim, Daniel de la Torre, Vice President, Res
 earch and Development, Constructive Bio, Saleha Patel, Head, Pipeline and C
 ommercialisation Strategy Operations, Constructive Bio, Ohad Yogev, Vice Pr
 esident, Discovery, ScionXBio, Martin Hey-Mogensen, Scientific Director, Em
 erging Obesity Mechanism Global Research, Novo Nordisk, Lora Heisler, Direc
 tor of Research, Rowett Institute of Nutrition and Health, University of Ab
 erdeen\n
DTSTAMP:20260812T092503Z
DTSTART;TZID=Europe/Berlin:20261028T073000
DTEND;TZID=Europe/Berlin:20261029T161500
SEQUENCE:0
TRANSP:OPAQUE
END:VEVENT
END:VCALENDAR